146 related articles for article (PubMed ID: 38284696)
1. Utilizing Pharmacogenomic Data for a Safer Use of Statins among the Emirati Population.
Alqasrawi MN; Al-Mahayri ZN; Alblooshi H; Alsafar H; Ali BR
Curr Vasc Pharmacol; 2024 Jan; ():e260124226224. PubMed ID: 38284696
[TBL] [Abstract][Full Text] [Related]
2. The frequency of major
Alrajeh K; AlAzzeh O; Roman Y
Pharmacogenomics; 2023 May; 24(7):381-398. PubMed ID: 37222158
[TBL] [Abstract][Full Text] [Related]
3. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
Cooper-DeHoff RM; Niemi M; Ramsey LB; Luzum JA; Tarkiainen EK; Straka RJ; Gong L; Tuteja S; Wilke RA; Wadelius M; Larson EA; Roden DM; Klein TE; Yee SW; Krauss RM; Turner RM; Palaniappan L; Gaedigk A; Giacomini KM; Caudle KE; Voora D
Clin Pharmacol Ther; 2022 May; 111(5):1007-1021. PubMed ID: 35152405
[TBL] [Abstract][Full Text] [Related]
4.
Rattanacheeworn P; Chamnanphon M; Thongthip S; Kittanamongkolchai W; Townamchai N; Avihingsanon Y; Udomnilobol U; Prueksaritanont T; Jianmongkol S; Chariyavilaskul P
Pharmgenomics Pers Med; 2020; 13():521-530. PubMed ID: 33122935
[TBL] [Abstract][Full Text] [Related]
5. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic variants affecting efficacy and toxicity of statins in a south Asian population from Sri Lanka.
Ranasinghe P; Sirisena N; Ariadurai JN; Vishnukanthan T; Thilakarathne S; Anandagoda G; Dissanayake VH
Pharmacogenomics; 2023 Oct; 24(15):809-819. PubMed ID: 37877238
[No Abstract] [Full Text] [Related]
7. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
[TBL] [Abstract][Full Text] [Related]
8. Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.
Licito A; Marotta G; Battaglia M; Benincasa G; Mentone L; Grillo MR; De Lucia V; Leonardi G; Bignucolo A; Comello F; Di Francia R; De Lucia D
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):469-477. PubMed ID: 31957862
[TBL] [Abstract][Full Text] [Related]
9. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
[TBL] [Abstract][Full Text] [Related]
10.
Božina T; Ganoci L; Karačić E; Šimičević L; Vrkić-Kirhmajer M; Klarica-Domjanović I; Križ T; Sertić Z; Božina N
Ann Hum Biol; 2022 Dec; 49(7-8):323-331. PubMed ID: 36382878
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics.
Lehtisalo M; Taskinen S; Tarkiainen EK; Neuvonen M; Viinamäki J; Paile-Hyvärinen M; Lilius TO; Tapaninen T; Backman JT; Tornio A; Niemi M
Br J Clin Pharmacol; 2023 Jan; 89(1):242-252. PubMed ID: 35942816
[TBL] [Abstract][Full Text] [Related]
12. The frequency of rs2231142 in
Alrajeh K; Roman YM
Pharmacogenomics; 2023 Jan; 24(1):15-26. PubMed ID: 36651271
[TBL] [Abstract][Full Text] [Related]
13. The frequency of rs2231142 in
AlAzzeh O; Roman YM
Pharmacogenomics; 2023 Feb; 24(3):173-182. PubMed ID: 36661065
[TBL] [Abstract][Full Text] [Related]
14.
Türkmen D; Bowden J; Masoli JAH; Melzer D; Pilling LC
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674010
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
[TBL] [Abstract][Full Text] [Related]
16. The lipid-lowering efficacy of rosuvastatin is associated with variations in SLCO1B1: a 12-month prospective cohort study.
Zakria M; Hussain A; Ahmad N; Ahmed N; Rauf MA; Siraj S
Eur Rev Med Pharmacol Sci; 2023 May; 27(10):4708-4717. PubMed ID: 37259755
[TBL] [Abstract][Full Text] [Related]
17. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
Generaux GT; Bonomo FM; Johnson M; Doan KM
Xenobiotica; 2011 Aug; 41(8):639-51. PubMed ID: 21425956
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.
Al-Mahayri ZN; Khasawneh LQ; Alqasrawi MN; Altoum SM; Jamil G; Badawi S; Hamza D; George L; AlZaabi A; Ouda H; Al-Maskari F; AlKaabi J; Patrinos GP; Ali BR
Hum Genomics; 2022 Sep; 16(1):42. PubMed ID: 36154845
[TBL] [Abstract][Full Text] [Related]
19. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
Lee HK; Hu M; Lui SSh; Ho CS; Wong CK; Tomlinson B
Pharmacogenomics; 2013 Aug; 14(11):1283-94. PubMed ID: 23930675
[TBL] [Abstract][Full Text] [Related]
20. Progression of precision statin prescribing for reduction of statin-associated muscle symptoms.
Petry NJ; Baye JF; Frear S; Jacobsen K; Massmann A; Schultz A; Heukelom JV; Christensen K
Pharmacogenomics; 2022 Jul; 23(10):585-596. PubMed ID: 35775396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
